Consider the CV Benefits of Different SGLT2 Inhibitors

You'll hear more about the CV benefits of SGLT2 inhibitors (canagliflozin, etc).

Reps will say canagliflozin (Invokana) is now approved to reduce CV events in adults with type 2 diabetes and CV disease...while empagliflozin (Jardiance) is only approved to reduce CV death.

But canagliflozin's approval is based on nonsignificant reductions in CV death, MI, or stroke...lumped into a significant composite outcome.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals